Skin cells from humans can be revamped into pro-clotting cells called platelets, according to a study published on November 22 in the Journal of Experimental Medicine (www.jem.org). Patients with diseases causing thrombocytopenia—platelet deficiency—often require repeated transfusions with platelets obtained from healthy donors.
But donor platelet isolation is expensive and labor intensive, and donor platelets can be attacked by the patient's immune systems as "foreign." Therefore, Koji Eto and colleagues sought a method for generating custom-made platelets from patients' own cells.
The team first reprogrammed human skin cells to a more primitive, stem cell–like state; these cells were then cultured in a cocktail of platelet-promoting soluble factors. The resulting platelets circulated and accumulated in blood clots when injected into platelet-deficient mice, behaving just like normal platelets.
Although additional work is needed to ensure that the culture-derived platelets function like normal healthy platelets, these findings represent an important step toward making patient-specific platelets clinically available.
About The Journal of Experimental Medicine
The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit www.jem.org.
Takayama, N., et al. 2010. J. Exp. Med. doi:10.1084/jem.20100844.
Journal
Journal of Experimental Medicine